- South Korea
- Founded 2015
Raising $ 300,000
Eazymation is the developer of Clouvir, a data leakage prevention service for enterprise file sync & sharing on the web.
• Testing integration with university course management tools and home trading systems
Pre-money Valuation10% Equity
Company DescriptionEazymation is the tech based start-up of virtualization and cloud.
Now Eazymation is developing Clouvir that DLP for EFSS(Data Leakage Prevention for Enterprise File Sync & Sharing).
3 people are in Eazymation who worked cloud start-up together and has IT development career.
We are the best team for making Clouvir.
Make it easy and simple.
That is our goal and mission.
Products & Services
Clouvir is Secured Enterprise File Sync & Sharing Web Service by cloud virtualization on any cloud storage and computing without any client and installation.
Typical EFSS (Enterprise File Sync&Share) market is faced data leakage problem.
Although, Encryption and DRM works like DLP (Data Loss/Leakage Prevention),
physically it’s not prevention.
Clouvir provides web based virtual application for real prevention.
According to a research,
35% of company is collaborating with external companies and employees regularly share files with external.
35% of EFSS companies got data problem.
Until now there are no leakage prevention solution.
Clouvir is DLP (Data leakage prevention) service for using EFSS by using virtualization.
It shares workspace not just file.
End user doesn’t need to know about complicated virtualization.
Just access Clouvir web-portal and use it.
EFSS stands for efficiency, BYOD, and collaboration.
Virtualization stands for strong security and strict management.
There is no common point of both, but now Clouvir would be.
Clouvir use virtualization for using EFSS.
We still know there’s no service is similar with Clouvir.
In technical point of view, WaaS (Workspace as a Service) is almost similar with Clouvir but different usage and target.
DLP (Data Loss Prevention: By using Encryption and DRM ) is totally different with Clouvir.